{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:32:00Z","timestamp":1777883520272,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100007261","name":"New York Academy of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp;amp; Addiction Journal"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Injectable opioid agonist treatment with hydromorphone (iOAT-H) is effective for persons who inject drugs (PWID) with opioid use disorder (OUD) but remains unavailable in the United States. Our objective was to determine interest in iOAT-H among syringe services program (SSP) participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We recruited PWID with OUD from SSPs in New York City. Interest in iOAT-H was assessed on a 4-point scale. We compared participants who were and were not interested in iOAT-H regarding sociodemographic characteristics and self-reported variables (past 30\u2009days): heroin use, public injection practices, and participation in illegal activity other than drug possession. Participants reported their preferred OUD treatment and reasons for these preferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 108 participants, most were male (69%), Hispanic (68%), and median age was 42\u2009years. The median number of prior OUD treatment episodes was 6 (interquartile range: 2-12). Most (65%) were interested in iOAT-H. Interested participants (vs not interested) reported, over the prior 30\u2009days, greater heroin use days (mean, 26.4 vs 22.3), injecting in public more times (median, 15 vs 6), and a higher percentage having participated in illegal activity (40% vs 16%). Preferences for OUD treatment were: iOAT-H (43%), methadone (39%), and buprenorphine (9%). Participants who preferred iOAT-H to conventional OUD treatments reported preferring injection as a route of administration and that available OUD treatments helped them insufficiently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>SSP participants with OUD reported high interest in iOAT-H. Participants had attempted conventional treatments but still used heroin almost daily. We identified PWID at risk for opioid-related harms who potentially could benefit from iOAT-H.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342231210552","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T05:08:09Z","timestamp":1703826489000},"page":"44-53","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants"],"prefix":"10.1177","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6904-4795","authenticated-orcid":false,"given":"Aaron D.","family":"Fox","sequence":"first","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, NY, USA"},{"name":"Montefiore Medical Center, Bronx, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Riback","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, NY, USA"},{"name":"Montefiore Medical Center, Bronx, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Perez-Correa","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, NY, USA"},{"name":"Montefiore Medical Center, Bronx, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Ohlendorf","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Ghiroli","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, NY, USA"},{"name":"Montefiore Medical Center, Bronx, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Czarina Navos","family":"Behrends","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"L\u00f3pez-Castro","sequence":"additional","affiliation":[{"name":"The City College of New York, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"key":"bibr1-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0962-y"},{"key":"bibr2-29767342231210552","doi-asserted-by":"crossref","DOI":"10.7249\/RR2693","volume-title":"Considering Heroin-Assisted Treatment and Supervised Drug Consumption Sites in the United States","author":"Kilmer B","year":"2018"},{"key":"bibr3-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.114.149195"},{"key":"bibr4-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.190344"},{"key":"bibr5-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2012.694598"},{"key":"bibr6-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102730"},{"key":"bibr7-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196405142702006"},{"issue":"5","key":"bibr8-29767342231210552","first-page":"347","volume":"67","author":"Joseph H","year":"2000","journal-title":"Mt Sinai J Med"},{"key":"bibr9-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003410.pub4"},{"key":"bibr10-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810635"},{"key":"bibr11-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2016.0109"},{"key":"bibr12-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.02.021"},{"key":"bibr13-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000505"},{"key":"bibr14-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.03.012"},{"key":"bibr15-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.03.003"},{"key":"bibr16-29767342231210552","unstructured":"Government of Canada. Government of Canada approves new treatment options for opioid use disorder and supports research, treatment and harm reduction projects in Ontario[News release]; 2019. Accessed November 18, 2023. Available at: https:\/\/www.canada.ca\/en\/health-canada\/news\/2019\/05\/government-of-canada-approves-new-treatment-options-for-opioid-use-disorder-and-supports-research-treatment-and-harm-reduction-projects-in-ontario.html"},{"issue":"4","key":"bibr17-29767342231210552","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/ADM.0000000000000934","volume":"16","author":"Jakubowski A","journal-title":"J Addict Med"},{"key":"bibr18-29767342231210552","doi-asserted-by":"crossref","first-page":"106674","DOI":"10.1016\/j.cct.2021.106674","volume":"114","author":"Perez-Correa A","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"bibr19-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1136\/jech.2007.069013"},{"key":"bibr20-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2015.1011820"},{"key":"bibr21-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.02.009"},{"key":"bibr22-29767342231210552","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2013.0183"},{"key":"bibr23-29767342231210552","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5"},{"issue":"3","key":"bibr24-29767342231210552","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","volume":"9","author":"McLellan AT","year":"1992","journal-title":"J Subst Abuse Treat"},{"key":"bibr25-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2013.10.015"},{"issue":"7","key":"bibr26-29767342231210552","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5055\/jom.2021.0643","volume":"17","author":"Epstein H","year":"2021","journal-title":"J Opioid Manag"},{"issue":"3","key":"bibr27-29767342231210552","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000001093","volume":"17","author":"Ohlendorf E","year":"2023","journal-title":"J Addict Med"},{"issue":"13","key":"bibr28-29767342231210552","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1080\/10826084.2022.2125273","volume":"57","author":"Riback L","year":"2022","journal-title":"Subst Use Misuse"},{"key":"bibr29-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1111\/add.15297"},{"key":"bibr30-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109380"},{"key":"bibr31-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1016\/s0376-8716(03)00097-8"},{"key":"bibr32-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2017.1310247"},{"key":"bibr33-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.648"},{"key":"bibr34-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.12.007"},{"key":"bibr35-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1111\/add.14442"},{"key":"bibr36-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.12.032"},{"key":"bibr37-29767342231210552","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000922"},{"key":"bibr38-29767342231210552","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6448a3"}],"container-title":["Substance Use &amp;amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342231210552","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342231210552","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342231210552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:48:53Z","timestamp":1777600133000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/29767342231210552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1177\/29767342231210552"],"URL":"https:\/\/doi.org\/10.1177\/29767342231210552","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]}}}